FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab

被引：82

作者：

Carlotti, Emanuela ^{[1
,2
]}

Palumbo, Giuseppe A. ^{[3
]}

Oldani, Elena ^{[1
]}

Tibullo, Daniele ^{[3
]}

Salmoiraghi, Silvia ^{[1
]}

Rossi, Andrea ^{[1
]}

Golay, Josee ^{[1
]}

Pulsoni, Alessandro ^{[4
]}

Foa, Robin ^{[4
]}

Rambaldi, Alessandro ^{[1
]}

机构：

[1] Osped Riuniti Bergamo, Div Ematol, Bergamo, Italy

[2] Barts & London Queen Marys Sch Med & Dent, CRUK Med Oncol Lab, London, England

[3] Univ Catania, Dipartimento Ematol, Sci Biomed, Catania, Italy

[4] Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Rome, Italy

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 08期

关键词：

Fc gamma R polymorphisms; follicular lymphoma; BCL2/IgH rearrangements;

D O I：

10.3324/haematol.11288

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We analyzed Fc gamma RIIIA-158V/F and Fc gamma RIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between Fc gamma RIIIA-158VV/VF and Fc gamma RIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH(+) cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.

引用

页码：1127 / 1130

页数：4

共 18 条

[1]

Boettcher S, 2004, ASH ANN M ABSTR, V104, P590

[2] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

[3] FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia [J].

Farag, SS ;

Flinn, IW ;

Modali, R ;

Lehman, TA ;

Young, D ;

Byrd, JC .

BLOOD, 2004, 103 (04) :1472-1474

[4] New treatment options have changed the survival of patients with follicular lymphoma [J].

Fisher, RI ;

LeBlanc, M ;

Press, OW ;

Maloney, DG ;

Unger, JM ;

Miller, TP .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8447-8452

[5] Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines [J].

Flieger, D ;

Renoth, S ;

Beier, I ;

Sauerbruch, T ;

Schmidt-Wolf, I .

CELLULAR IMMUNOLOGY, 2000, 204 (01) :55-63

[6]

Golay J, 2000, BLOOD, V95, P3900

[7] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[8] FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma [J].

Kim, Dong Hwan ;

Du Jung, Hee ;

Kim, Jong Gwang ;

Lee, Je-Jung ;

Yang, Deok-Hwan ;

Park, Yeon Hee ;

Do, Young Rok ;

Shin, Ho Jin ;

Kim, Min Kyoung ;

Hyun, Myung Soo ;

Sohn, Sang Kyun .

BLOOD, 2006, 108 (08) :2720-2725

[9] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma [J].

Marcus, R ;

Imrie, K ;

Belch, A ;

Cunningham, D ;

Flores, E ;

Catalano, J ;

Solal-Celigny, P ;

Offner, F ;

Walewski, J ;

Raposo, J ;

Jack, A ;

Smith, P .

BLOOD, 2005, 105 (04) :1417-1423

[10]

Marcus RE, 2006, ASH ANN M, V108, P481

← 1 2 →